Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Cell MedX Corp    

SummaryChartsNewsCompany 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Insider Trading Activity Cell MedX Corp (NASDAQ:CMXC) – Major Shareholder Bought 5,000 shares of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2017 | 04:45pm CEST

Insider Trading Activity For Cell MedX Corp (NASDAQ:CMXC)

Richard Jeffs , Major Shareholder of Cell MedX Corp (NASDAQ:CMXC) reportedly Bought 5,000 shares of the company’s stock at an average price of 0.35 for a total transaction amount of $1,750.00 SEC Form

Analyst Ratings For Cell MedX Corp (NASDAQ:CMXC)
These are No ratings tracked in the last 12 months. .
The current consensus rating for Cell MedX Corp (NASDAQ:CMXC) is N/A (Score: NaN) with a consensus target price of N/A

About Cell MedX Corp (NASDAQ:CMXC)
Cell MedX Corp. is a development-stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases, such as diabetes, by developing technologies to help manage the illness and related complications. The Company, through its subsidiary, Avyonce Cosmedics Inc. (Avyonce), is engaged in reselling and marketing spa technology and equipment to the beauty and wellness industry. Avyonce is involved in carrying out observational studies using eBalance Technology. The eBalance Technology is used for the use of micro currents for the treatment of diabetes and related ailments. Avyonce also provides continuing education to the estheticians and healthcare professionals in the field of medical aesthetics. The Company is engaged in developing a family of devices based on the eBalance Technology.

Recent Trading Activity for Cell MedX Corp (NASDAQ:CMXC)
Shares of Cell MedX Corp closed the previous trading session at 0.375 up +0.020 5.61% with 1,588 shares trading hands.

The post Insider Trading Activity Cell MedX Corp (NASDAQ:CMXC) – Major Shareholder Bought 5,000 shares of Stock appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELL MEDX CORP
05/15 INSIDER TRADING ACTIVITY CELL MEDX C : CMXC) – Major Shareholder Bought 5,..
04/26 CELL MEDX CORP : Cell MedX Corp. Moves its Manufacturing to British Columbia, Ca..
04/26 Cell MedX Corp. Moves its Manufacturing to British Columbia, Canada
04/26 CELL MEDX : Moves its Manufacturing to British Columbia, Canada
04/14 CELL MEDX : Management's Discussion and Analysis of Financial Condition and Resu..
04/13 INSIDER TRADING ACTIVITY CELL MEDX C : CMXC) – Major Shareholder Bought 5,..
03/28 CELL MEDX CORP : Cell MedX Corp. Announces FDA Registration and Update on Clinic..
03/28 Cell MedX Corp. Announces FDA Registration and Update on Clinical Observation..
03/28 CELL MEDX : Announces FDA Registration and Update on Clinical Observational Stud..
03/25 INSIDER TRADING ACTIVITY CELL MEDX C : CMXC) – Major Shareholder Bought 21..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
Advertisement
Chart CELL MEDX CORP
Duration : Period :
Cell MedX Corp Technical Analysis Chart | US15115X1072 | 4-Traders
Full-screen chart
Managers
NameTitle
Frank E. Mcenulty President, Chief Executive Officer & Director
Bradley Hargreaves Director, VP-Technology & Operations
Yanika S. Silina CFO, Secretary, Treasurer & Director
John David Sanderson Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELL MEDX CORP132.08%0
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.86%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..24.14%48 380
ACTELION LTD26.30%30 602
More Results